Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data [Seeking Alpha]
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates [Yahoo! Finance]
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data